<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383445</url>
  </required_header>
  <id_info>
    <org_study_id>VIVA</org_study_id>
    <nct_id>NCT03383445</nct_id>
  </id_info>
  <brief_title>Transcatheter Aortic Valve Replacement Versu Surgical Aortix Valve Replacement for Treating Elderly Patients With Severe Aortic Stenosis and Small Aortic Annuli: A Prospective Randomized Study The VIVA Trial</brief_title>
  <official_title>Transcatheter Aortic Valve Replacement Versu Surgical Aortix Valve Replacement for Treating Elderly Patients With Severe Aortic Stenosis and Small Aortic Annuli: A Prospective Randomized Study The VIVA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date, no formal, randomized, prospective, head-to-head comparisons of surgical aortic
      valve replacement (SAVR) versus transcatheter aortic valve replacement (TAVR) have been
      undertaken in the severe aortic stenosis (AS) population with small aortic annuli. Objectives
      of the present study are to compare the hemodynamic performance (incidence of severe PPM and
      ≥ moderate AR) and clinical outcomes (death, stroke, major or life threatening bleeding)
      between TAVR and SAVR in patients with severe AS and small aortic annuli.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized open-label trial including patients with
      severe AS and small aortic annulus (mean aortic annuli diameter ˂22mm, evaluated by 3D-CT or
      3D-TEE). Patients will be randomized in a 1:1 fashion to either TAVR or SAVR. The TAVR
      procedure will be performed with the Edwards SAPIEN 3 valve (20 or 23mm) or the CoreValve
      Evolut R or Evolut PRO valve system (23 or 26 mm).New iterations of these valve models may
      also be included. The SAVR procedure will be performed using standard techniques, with no
      limitation in terms of type and size of the valve prosthesis or surgical procedure (e.g.
      enlargement of the aortic root). For both TAVR and SAVR, the choice of the type and size of
      valve, access route (for TAVR), utilization of additional procedures such as root enlargement
      will be left at the discretion of heart team of the site treating the patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Anticipated">May 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized in a 1:1 fashion to either TAVR or SAVR</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Valve performance: rate of prothesis-patient mismatch (PPM) and/or aortic regurgitation (AR)</measure>
    <time_frame>60 days</time_frame>
    <description>Severe PPM [defined as an indexed aortic valve area ≤0.65 cm2/m2 ] and/or ≥moderate AR [Valve Academic Research Consortium-2 (VARC-2) definition].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of PPM</measure>
    <time_frame>60 days, 1 year and 5 years</time_frame>
    <description>Rate of moderate or severe PPM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of AR</measure>
    <time_frame>60 days, 1 year and 5 years</time_frame>
    <description>Rate of moderate or severe AR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined endpoints: rate of AR or PPM</measure>
    <time_frame>1 year and 5 years</time_frame>
    <description>Moderate or severe AR or severe PPM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transvalvular gradient</measure>
    <time_frame>60 days, 1 year and 5 years</time_frame>
    <description>Mean transvalvular gradient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined endpoints: LVEF and LV</measure>
    <time_frame>60 days, 1 year and 5 years</time_frame>
    <description>Changes in LVEF and LV hypertrophy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days, 1 year and 5 years</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days, 1 year and 5 years</time_frame>
    <description>Stroke (Valve Academic Research Consortium-2 (VARC-2) definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>30 days, 1 year and 5 years</time_frame>
    <description>Major or life threatening bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of new atrial fibrillation</measure>
    <time_frame>30 days, 1 year and 5 years</time_frame>
    <description>Rate of new-onset atrial fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Safety endpoint</measure>
    <time_frame>30 days, 1 year and 5 years</time_frame>
    <description>Death, stroke, major/life threatening bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac re-hospitalization</measure>
    <time_frame>30 days, 1 year and 5 years</time_frame>
    <description>Need for cardiac re-hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of hospital stay</measure>
    <time_frame>For the duration of hospital stay</time_frame>
    <description>Length of the hospitalization for the TAVR or SAVR procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>30 days, 1 year and 5 years</time_frame>
    <description>Questionnaire, visual scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>30 days, 1 year and 5 years</time_frame>
    <description>Exercise capacity as evaluated by the six-minute walk test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Degenerative Aortic Valve Disease</condition>
  <condition>Aortic Stenosis</condition>
  <condition>Aortic Regurgitation</condition>
  <arm_group>
    <arm_group_label>TAVR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local abesthesia, Imaging guidance during the TAVR procedure, and post-procedural TAVR management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAVR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>SAVR procedure will be performed using standard techniques, with no limitation in terms of type and size of the valve prosthesis or surgical procedure (e.g. enlargement of the aortic root).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Edwards</intervention_name>
    <description>The TAVR procedure will be performed with the Edwards SAPIEN XT or SAPIEN 3 valve (20 0r 23 mm).</description>
    <arm_group_label>TAVR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CoreValve</intervention_name>
    <description>The TAVR procedure will be performed with the CoreValve Evolut R valve system (23 or 26 mm).</description>
    <arm_group_label>TAVR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard</intervention_name>
    <description>The choice of the type and size of valve, utilization of additional procedures such as root enlargement will be left at the discretion of heart team of the treating the patient.</description>
    <arm_group_label>SAVR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥65 years-old diagnosed with severe AS (defined as: jet velocity ≥ 4.0 m/s or
             mean gradient ≥ 40 mmHg or velocity ratio &lt;0.25 AND aortic valve area ≤ 1.0 cm2 or
             aortic valve area index ≤ 0.6 cm2/m2; OR mean gradient &gt;30 mmHg AND aortic valve area
             ≤ 1.0 cm2 or aortic valve area index ≤ 0.6 cm2/m2 AND &gt;1200 Agatston units for women
             or &gt;2000 Agatston units for men as determined by non-contrast CT).

          -  Small aortic annulus defined as a mean aortic annulus diameters ˂22 mm as measured by
             3D-computed tomography (CT) and/or 3D-transesophageal echocardiography (TEE).

        Exclusion Criteria:

          -  Prohibitive surgical risk as determined by the Heart Team

          -  Severe pulmonary disease

          -  Dialysis-dependency

          -  Porcelain aorta

          -  Aortic root dilatation &gt;45 mm

          -  Coronary artery disease (CAD) not treatable by percutaneous coronary intervention
             (PCI) or coronary artery bypass grafting (CABG), or SYNTAX score &gt;32 (in the absence
             of prior revascularization) 42

          -  Non-calcific aortic stenosis

          -  Severe mitral regurgitation

          -  Moderate-to-severe tricuspid regurgitation requiring surgical repair
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Josep Rodés-Cabau, MD</last_name>
    <phone>418-656-8711</phone>
    <email>josep.rodes@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie Pelletier Beaumont, MSc</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3929</phone_ext>
    <email>emilie.pelletier-beaumont@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IUCPQ</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Rodes-Cabau, MD</last_name>
      <phone>418-656-8711</phone>
      <email>josep.rodes@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Emilie Pelletier Beaumont, MSc</last_name>
      <phone>418-656-8711</phone>
      <email>emilie.pelletier-beaumont@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Josep Rodes-Cabau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>Josep Rodes-Cabau</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

